Atomo & Access Bio sign deal for rapid antigen test
Filed with ASX · · 3 pages · English
with Access Bio LLC, (Access), previously announced to ASX on 28 July 2020. Under the expanded partnership, Atomo will have non-exclusive rights to market and distribute COVID-19 Antigen Test, subject to obtaining the required regulatory approvals in each jurisdiction. The Atomo COVID-19 rapid antigen test is a nasopharyngeal swab test designed to screen for antigens produced in response to COVID-
Story so far
Earlier from Atomo Diagnostics
- DIVOC Labs to sell Atomos COVID-19 test in India
- FY20 Results Presentation
- Atomo receives TGA approval for COVID19 antibody test
- Atomo & Access Bio enter North American COVID-19 partnership
- Quarterly Activity Report & Appendix 4C - 30 June 2020
Later from Atomo Diagnostics
- Atomo receives TGA approval for COVID19 antigen test
- Quarterly Activity Report & Appendix 4C - 30 September 2020
- Managing Directors AGM Presentation
- Atomo receives TGA approval for AtomoRapid HIV (1&2) test
- Atomo provides update on its HIV Rapid Test business
Follow Atomo Diagnostics into a list and get an email when it puts out news.
Follow Atomo Diagnostics